We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel–Mediated Cardiotoxicity.
- Authors
Hackl, Benjamin; Todt, Hannes; Kubista, Helmut; Hilber, Karlheinz; Koenig, Xaver
- Abstract
Psilocybin, a hallucinogen contained in "magic" mushrooms, holds great promise for the treatment of various psychiatric disorders, and early clinical trials are encouraging. Adverse cardiac events after intake of high doses of psilocybin and a trial reporting QT interval prolongation in the electrocardiogram attributed to the drug's main metabolite, psilocin, gave rise to safety concerns. Here we show that clinical concentrations of psilocin do not cause significant human ether-a-go-go-related gene (hERG) potassium channel inhibition, a major risk factor for adverse cardiac events. We conclude that hERG channel blockage by psilocin is not liable for psilocybin- associated cardiotoxic effects.
- Subjects
PSILOCYBIN; MENTAL illness; CARDIOTOXICITY; POTASSIUM channels; POTASSIUM; CRIME &; the press
- Publication
International Journal of Neuropsychopharmacology, 2022, Vol 25, Issue 4, p280
- ISSN
1461-1457
- Publication type
Article
- DOI
10.1093/ijnp/pyab085